- Successful investment
- Unsuccessful investment
Nextech Invest relies on a stringent process to select portfolio companies. This process begins by connecting to companies through a global network of key opinion leaders, scientific experts, business partners, and academic sources. Next, a comprehensive assessment of the target company is carried out by the Nextech investment team in conjunction with our Scientific Board to determine whether the company meets out investment criteria.
To date, we have assessed over 1100 cancer companies world-wide covering more than 100 oncology indications. Since 2007 we have invested in 16 exceptional companies.
Traditional treatments include chemotherapy, radiation, and surgery with the objective to eradicate cancer cells while sparing healthy cells. Most current therapies come with undesirable side effects and often lack significant efficacy. With ongoing research, treatments are becoming increasingly effective and safe.
Your eMail have been successfully registered.Close